FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288442693> ?p ?o ?g. }

• W4288442693 endingPage "e2224163" @default.
• W4288442693 startingPage "e2224163" @default.
• W4288442693 abstract "<h3>Importance</h3> Evidence for improved clinical outcomes with long-acting injectable antipsychotics (LAIAs) vs oral antipsychotics (OAs) is limited in Asian populations and special patient groups, including older people (>65 years), people with substance use, and early initiators of LAIAs. <h3>Objective</h3> To compare the risk of disease relapse, health care use, and adverse events associated with the use of LAIAs vs OAs among people in Hong Kong with schizophrenia. <h3>Design, Setting, and Participants</h3> In this self-controlled case series study, individuals with a diagnosis of schizophrenia who were prescribed LAIAs and OAs between January 1, 2004, and December 31, 2019, were identified from the Clinical Database Analysis and Reporting System of the Hong Kong Hospital Authority. Data analysis was conducted from May to August in 2021. <h3>Exposures</h3> Use of LAIAs vs OAs. <h3>Main Outcomes and Measures</h3> Risk of disease relapse (hospitalizations for psychiatric disorders, hospitalizations for schizophrenia, and suicide attempts), health care use (all-cause emergency department visits and hospitalizations), and adverse events (hospitalizations for somatic disorders, hospitalizations for cardiovascular diseases, and extrapyramidal symptoms) between the period in which patients were treated with LAIAs and the period in which patients were treated with OAs were compared using Poisson regression. <h3>Results</h3> Of the 70 396 individuals with schizophrenia (37 200 women [52.8%]; mean [SD] age, 44.2 [15.8] years), 23 719 (33.7%) were prescribed both LAIAs and OAs. Compared with OAs, LAIAs were associated with a lower risk of hospitalizations for any cause (n = 20 973; incidence rate ratio [IRR], 0.63 [95% CI, 0.61-0.65]), hospitalizations for psychiatric disorders (n = 19 283; IRR, 0.52 [95% CI, 0.50-0.53]), hospitalizations for schizophrenia (n = 18 385; IRR, 0.53 [95% CI, 0.51-0.55]), and incident suicide attempts (n = 1453; IRR, 0.56 [95% CI, 0.44-0.71]). During full treatment with LAIAs, there was a reduction in hospitalizations for somatic disorders (n = 15 396; IRR, 0.88 [95% CI, 0.85-0.91]), hospitalizations for cardiovascular diseases (n = 3710; IRR, 0.88 [95% CI, 0.81-0.96]), and extrapyramidal symptoms (n = 22 182; IRR, 0.86 [95% CI, 0.82-0.91]) compared with full treatment with OAs. No significant difference was found for emergency department visits. Similar associations were observed during the subsequent treatment periods (beyond 90 days) and among older people and those with substance use, except for an increased risk of extrapyramidal symptoms among older people when initiating LAIAs (first 90 days). Compared with late initiators, early LAIA initiators had a greater reduction in these outcome events. <h3>Conclusions and Relevance</h3> This self-controlled case series study of people in Hong Kong with schizophrenia suggests that LAIAs were associated with a lower risk of disease relapse and hospitalization than OAs, without an increased risk of adverse events. Clinicians should more broadly consider the long-term use of LAIAs for Chinese people with schizophrenia, especially early in the course of illness." @default.
• W4288442693 created "2022-07-29" @default.
• W4288442693 creator A5003358736 @default.
• W4288442693 creator A5026731946 @default.
• W4288442693 creator A5027126143 @default.
• W4288442693 creator A5028633730 @default.
• W4288442693 creator A5029330906 @default.
• W4288442693 creator A5033569206 @default.
• W4288442693 creator A5052884442 @default.
• W4288442693 creator A5054006971 @default.
• W4288442693 creator A5066384550 @default.
• W4288442693 creator A5082409466 @default.
• W4288442693 creator A5090788920 @default.
• W4288442693 date "2022-07-28" @default.
• W4288442693 modified "2023-10-05" @default.
• W4288442693 title "Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia" @default.
• W4288442693 cites W1533343980 @default.
• W4288442693 cites W1969080412 @default.
• W4288442693 cites W1995034182 @default.
• W4288442693 cites W2069784839 @default.
• W4288442693 cites W2081622568 @default.
• W4288442693 cites W2082795262 @default.
• W4288442693 cites W2117675290 @default.
• W4288442693 cites W2129088827 @default.
• W4288442693 cites W2139645720 @default.
• W4288442693 cites W2159155203 @default.
• W4288442693 cites W2345609563 @default.
• W4288442693 cites W2397033370 @default.
• W4288442693 cites W2551841443 @default.
• W4288442693 cites W2618699239 @default.
• W4288442693 cites W2623053349 @default.
• W4288442693 cites W2735301415 @default.
• W4288442693 cites W2737635599 @default.
• W4288442693 cites W2948185891 @default.
• W4288442693 cites W2955419021 @default.
• W4288442693 cites W2967501807 @default.
• W4288442693 cites W2982685163 @default.
• W4288442693 cites W2998819434 @default.
• W4288442693 cites W3006230641 @default.
• W4288442693 cites W3020727138 @default.
• W4288442693 cites W3027866619 @default.
• W4288442693 cites W3029731088 @default.
• W4288442693 cites W3043420940 @default.
• W4288442693 cites W3120194488 @default.
• W4288442693 cites W3124121244 @default.
• W4288442693 cites W3149233635 @default.
• W4288442693 cites W3160438352 @default.
• W4288442693 cites W3195601230 @default.
• W4288442693 cites W4200066447 @default.
• W4288442693 cites W4225468996 @default.
• W4288442693 cites W4234506066 @default.
• W4288442693 cites W4235145342 @default.
• W4288442693 cites W4239245700 @default.
• W4288442693 cites W4249695431 @default.
• W4288442693 cites W4250498198 @default.
• W4288442693 cites W4253084711 @default.
• W4288442693 cites W71588257 @default.
• W4288442693 doi "https://doi.org/10.1001/jamanetworkopen.2022.24163" @default.
• W4288442693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35900760" @default.
• W4288442693 hasPublicationYear "2022" @default.
• W4288442693 type Work @default.
• W4288442693 citedByCount "6" @default.
• W4288442693 countsByYear W42884426932022 @default.
• W4288442693 countsByYear W42884426932023 @default.
• W4288442693 crossrefType "journal-article" @default.
• W4288442693 hasAuthorship W4288442693A5003358736 @default.
• W4288442693 hasAuthorship W4288442693A5026731946 @default.
• W4288442693 hasAuthorship W4288442693A5027126143 @default.
• W4288442693 hasAuthorship W4288442693A5028633730 @default.
• W4288442693 hasAuthorship W4288442693A5029330906 @default.
• W4288442693 hasAuthorship W4288442693A5033569206 @default.
• W4288442693 hasAuthorship W4288442693A5052884442 @default.
• W4288442693 hasAuthorship W4288442693A5054006971 @default.
• W4288442693 hasAuthorship W4288442693A5066384550 @default.
• W4288442693 hasAuthorship W4288442693A5082409466 @default.
• W4288442693 hasAuthorship W4288442693A5090788920 @default.
• W4288442693 hasBestOaLocation W42884426931 @default.
• W4288442693 hasConcept C118552586 @default.
• W4288442693 hasConcept C126322002 @default.
• W4288442693 hasConcept C187212893 @default.
• W4288442693 hasConcept C197934379 @default.
• W4288442693 hasConcept C2776412080 @default.
• W4288442693 hasConcept C2779134260 @default.
• W4288442693 hasConcept C2780494398 @default.
• W4288442693 hasConcept C2780616385 @default.
• W4288442693 hasConcept C2908647359 @default.
• W4288442693 hasConcept C71924100 @default.
• W4288442693 hasConcept C73269764 @default.
• W4288442693 hasConcept C99454951 @default.
• W4288442693 hasConceptScore W4288442693C118552586 @default.
• W4288442693 hasConceptScore W4288442693C126322002 @default.
• W4288442693 hasConceptScore W4288442693C187212893 @default.
• W4288442693 hasConceptScore W4288442693C197934379 @default.
• W4288442693 hasConceptScore W4288442693C2776412080 @default.
• W4288442693 hasConceptScore W4288442693C2779134260 @default.
• W4288442693 hasConceptScore W4288442693C2780494398 @default.
• W4288442693 hasConceptScore W4288442693C2780616385 @default.
• W4288442693 hasConceptScore W4288442693C2908647359 @default.

• next